CION Ameerpet
Von Hippel-Lindau (VHL) is a rare inherited condition that causes benign hemangioblastoma brain tumours, along with growths elsewhere in the body. CION explains the genetics, arranges testing, and coordinates the lifelong surveillance that keeps you a step ahead — calmly and clearly.
Von Hippel-Lindau disease is a rare inherited condition caused by a change (mutation) in a single gene — the VHL gene. This gene normally acts as a brake on the growth of blood vessels. When it is faulty, that brake is weakened, and people tend to develop tumours and cysts in several parts of the body over their lifetime.
In the nervous system, the classic VHL tumour is a hemangioblastoma — a benign (non-cancerous), blood-vessel-rich growth that most often appears in the cerebellum (the balance centre at the back of the brain), the brainstem, the spinal cord, and the retina of the eye. VHL also raises the risk of tumours elsewhere, especially the kidneys. The important message for anyone newly told they have VHL is this: a diagnosis is not a verdict. It is the start of a clear, planned surveillance programme that catches changes early, when they are simplest to treat. This page explains the genetics, how VHL is diagnosed, why family testing matters, and the treatment paths — written and reviewed by the CION neuro-oncology team. For context on benign and malignant tumours, see our wider brain tumour overview.
Von Hippel-Lindau disease affects roughly 1 in 36,000 people and is autosomal dominant — meaning a child of an affected parent has about a 50% chance of inheriting the faulty gene. Guidance from bodies such as the EANO and NCCN emphasises that hemangioblastomas are the most common nervous-system tumour in VHL, and that finding more than one hemangioblastoma — or one at a young age — should prompt testing for VHL, because it changes lifelong surveillance and family screening.
VHL is a whole-body condition, which is exactly why it needs a coordinated plan rather than piecemeal care. Different tumours affect different organs, and not everyone with VHL develops all of them. The most important sites are:
Because these sit in different organs, VHL care is a team effort. At CION, the neuro-oncology team holds the brain and spine imaging together with the wider surveillance, so nothing slips between clinics. If you have just been diagnosed, talk to a CION specialist about building your surveillance plan.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether you've just been told you have VHL, have more than one hemangioblastoma, or have a relative with the condition, our team will explain the genetics, arrange testing, and build your surveillance plan — calmly and without pressure.
Understanding the genetics is often the part that eases the most anxiety, because it turns a frightening unknown into something with clear odds and a clear plan.
VHL is caused by a mutation in one gene — the VHL gene, a tumour-suppressor gene that normally helps limit blood-vessel growth. When one copy of this gene is faulty, cells lose part of that control and are more likely to form the tumours and cysts seen in VHL.
VHL is inherited in an autosomal dominant pattern. In plain terms, this means a person with VHL has a 1 in 2 (50%) chance of passing the faulty gene to each child, regardless of the child's sex. Some people are the first in their family to have VHL (a new mutation), while others inherit it from a parent. A genetic test can clarify which applies to you.
Even within the same family, VHL can look different from one person to the next — some develop mainly brain and eye tumours, others mainly kidney or adrenal ones. This variability is why everyone with VHL needs their own tailored surveillance plan rather than a one-size-fits-all schedule.
VHL is diagnosed by putting together three things: your tumour pattern, your family history, and a genetic blood test.
A specialist will suspect VHL — and arrange testing — when someone has any of the following: more than one hemangioblastoma; a hemangioblastoma at a young age; a hemangioblastoma in the retina of the eye; clear-cell kidney cancer at a young age; or a relative already known to have VHL. Even a single hemangioblastoma in a young person is often enough to prompt the conversation.
A simple blood test analyses the VHL gene for a mutation. A positive result confirms VHL and allows lifelong surveillance to begin. A negative result in the right setting can be reassuring. Testing is best done alongside genetic counselling, so you understand what the result means for you and your family before and after the test.
Because VHL is inherited, a confirmed diagnosis means first-degree relatives — parents, brothers, sisters, and children — should be offered predictive genetic testing. Those who carry the gene can start surveillance early; those who do not are spared unnecessary scans and worry. At CION we help arrange and coordinate this family testing so no one is left uncertain. To learn how these tumours look on a scan, see our hemangioblastoma diagnosis page.
Because VHL tumours can appear over a lifetime, the single most powerful thing you can do is find changes early — when treatment is simplest and organs are most likely to be preserved. That is what a structured surveillance programme does. A typical plan, tailored to your age and findings, includes:
The exact schedule follows recognised VHL surveillance guidance and is adjusted as you grow older or if something is found. CION's advantage is coordination: your brain and spine MRIs, your eye checks, and your abdominal imaging are tracked together in one pathway — with your case reviewed by a tumour board — rather than you juggling separate, disconnected appointments.
The biggest cancer risk in Von Hippel-Lindau disease is not in the brain at all — it is clear-cell kidney (renal) cancer. That is why regular abdominal imaging of the kidneys is just as important as brain MRI in VHL. Catching kidney tumours while they are small often allows kidney-sparing surgery, preserving healthy kidney tissue — a key reason lifelong, whole-body surveillance genuinely changes outcomes.
A hemangioblastoma is treated based on whether it is growing or causing symptoms — not simply because it exists. Because VHL causes tumours over time, the aim is to treat what needs treating while sparing you unnecessary operations. NCCN and EANO recognise all three approaches below.
For small, symptom-free tumours — very common in VHL, where several tumours may be found on a scan — the safest plan is often to monitor with repeat MRI. Because these tumours can stay stable for years, this avoids treatment risks unless and until a tumour grows or a surrounding cyst enlarges.
For accessible tumours that are growing or causing symptoms, surgical removal is the mainstay. Because hemangioblastomas are highly vascular, surgery is carefully planned. At CION this is coordinated with our accredited neurosurgical partners, who perform the operation, while our team manages your imaging, any radiation, and the wider VHL plan.
For tumours that are small, deep, surgically difficult, or multiple — which is common in VHL — stereotactic radiosurgery delivers highly focused radiation from many angles at once, with no incision. Despite the name, no cutting is involved. CION plans and delivers radiation directly as part of coordinated radiosurgery and specialist care.
VHL care spans several specialties, so it helps to know exactly who does what at CION:
This matters most in VHL, where care crosses the brain, spine, eyes, and kidneys over a lifetime. One coordinated team holding your imaging, your decisions, and your follow-up together means you are not bounced between disconnected providers. We walk this journey with you.
Most VHL brain tumours are benign and slow-growing, which means you usually have time to make calm, well-informed decisions. A second opinion is especially worthwhile if:
At CION, your case goes to a multidisciplinary tumour board, and we offer a free written second opinion after a 45-minute consultation. Book your free consultation or call 18002028726. You may also want to read our detailed page on hemangioblastoma and the VHL link, or the wider brain tumour treatment options at CION.
Get a free written second opinion from CION's tumour board — particularly valuable if your VHL surveillance plan, genetic testing, and family screening haven't yet been properly explained to you.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Von Hippel-Lindau disease is a rare inherited condition caused by a change (mutation) in the VHL gene. This gene normally helps control the growth of blood vessels. When it is faulty, people tend to develop tumours and cysts in several parts of the body over their lifetime — most commonly hemangioblastomas in the brain, spinal cord, and retina (the back of the eye), along with a higher risk of kidney tumours, pancreatic cysts, and adrenal growths. Many of these tumours are benign, but they need lifelong monitoring so they can be treated early. VHL affects roughly 1 in 36,000 people and is passed down in families. If you have been diagnosed, it does not mean every tumour will be dangerous — it means you have a clear plan for catching changes early.
A hemangioblastoma is a benign, blood-vessel-rich brain tumour and it is the most common nervous-system tumour in VHL. In VHL, people often develop more than one hemangioblastoma over time — in the cerebellum, brainstem, spinal cord, and retina. This is the key difference from a one-off (sporadic) hemangioblastoma: VHL tends to cause multiple tumours across a lifetime, which is why lifelong MRI surveillance matters. In fact, finding more than one hemangioblastoma, or one at a young age, is a strong clue that VHL should be tested for. You can read more on our dedicated hemangioblastoma page.
Mostly, no. The brain and spinal-cord tumours seen in VHL are hemangioblastomas, which are benign (non-cancerous) WHO Grade 1 tumours. They do not spread the way cancer does. However, because they grow in tight, delicate spaces — or develop a surrounding fluid-filled cyst — they can press on nearby structures and cause symptoms, so they are watched carefully and treated when needed. The main cancer risk in VHL comes from elsewhere in the body, particularly kidney (renal cell) cancer, which is why whole-body surveillance is part of VHL care. Understanding that the brain tumours themselves are usually benign is often a relief for families who feared the worst.
VHL is diagnosed through a combination of your tumour pattern, family history, and a genetic blood test that looks for a mutation in the VHL gene. Suspicion is raised when someone has more than one hemangioblastoma, a hemangioblastoma at a young age, a retinal (eye) tumour, or a relative with VHL. Because VHL is inherited, a confirmed diagnosis means first-degree relatives (parents, siblings, children) should be offered genetic testing and counselling — those who carry the gene begin surveillance early, and those who do not are reassured. At CION we arrange genetic assessment and coordinate this family screening so no one is left uncertain.
Because VHL tumours can appear over a lifetime, regular, planned surveillance is the cornerstone of care — the goal is to find changes early, when treatment is simpler. Typical monitoring includes MRI of the brain and spine (usually every 1–2 years), eye examinations for retinal hemangioblastomas, and abdominal imaging of the kidneys, pancreas, and adrenal glands. The exact schedule is tailored to your age and findings, following recognised VHL surveillance guidance. CION coordinates this multi-organ programme so your brain, spine, and body imaging are tracked together in one pathway — rather than you chasing separate appointments across disconnected clinics.
Treatment is guided by whether a hemangioblastoma is growing or causing symptoms — not simply by its presence. Small, symptom-free tumours are often monitored with repeat MRI, since they can stay stable for years. When a tumour grows or causes problems, options are surgical removal — coordinated with our accredited neurosurgical partners — or stereotactic radiosurgery (focused radiation with no incision) for small, deep, or multiple tumours. Because VHL causes tumours over time, the plan is long-term and multidisciplinary. CION delivers imaging, radiosurgery planning, symptom management, and coordination directly, and works with neurosurgical partners when an operation is needed.
CION delivers the oncology-led parts of VHL brain care directly — MRI diagnosis and surveillance, stereotactic radiosurgery planning and delivery, steroid and symptom management, genetic-assessment coordination, and supportive care. When a hemangioblastoma needs to be surgically removed, that operation is coordinated with our accredited neurosurgical partners, who perform the surgery, while our team manages your imaging, any radiation, and the overall plan. Because VHL affects several organs, we also help coordinate your wider surveillance (eyes, kidneys, and other sites). You get one connected pathway and a tumour board reviewing your case — not a series of disconnected referrals.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.